Publications
Tocagen’s research and technology has been included in numerous peer-reviewed scientific journals and presented at scientific and medical meetings. Browse the articles and presentations below to learn more.
Presentations
The addition of Toca 511 and 5-FC to temozolomide improves response in a temozolomide-resistant murine glioblastoma model and correlates with Toca 511 dose
AACR 2019 poster presentation by Maria E. Rodriguez-Aguirre research associate, microscopy lead at Tocagen.
Review the poster.
Immunologic trends associated with recurrent high grade glioma patient outcomes in a Phase 1 clinical trial of Toca 511 and Toca FC
2018 SNO poster presentation by William Accomando, Ph.D., research scientist, R&D diagnostics at Tocagen.
Review the poster.
PD-L1 Checkpoint Blockade Using a Single-Chain Variable Fragment Targeting PD-L1 Delivered by Retroviral Replicating Vector (Toca 521) Enhances Anti-Tumor Effect in Cancer Models
2018 CADDDC oral presentation by Amy Lin, Ph.D., associate director of experimental virology at Tocagen.
Review the presentation.
Enhanced Efficacy and Combinability of Low Dose Toca 511 and 5-FC with Metronomic Chemotherapy in Preclinical Models
2018 SITC poster presentation by Sophie Viaud, Ph.D., research scientist II, translational research, immuno-oncology at Tocagen.
Review the poster.
Effects of Toca 511 & Toca FC on tumor microenvironment and peripheral blood populations in patients with advanced malignancies
2018 CRI-CIMT-EATI-AACR poster presentation. Lead author: Jaime Merchan, M.D., director, Phase 1 clinical trials program at Sylvester Comprehensive Cancer Center; associate professor of medicine at the University of Miami Miller School of Medicine.
Review the poster.
24th Annual Meeting of Japan Society of Gene & Cell Therapy (JSGCT) Presentation
2018 JSGCT oral presentation by Nick Boyle, Ph.D., vice president, business development and marketing at Tocagen.
Review the presentation.
Treatment of Recurrent High Grade Glioma Patients with the Retroviral Replicating Vector Toca 511 & Toca FC Resulted in Durable Responses and Survival Lasting 3 Years of Longer: Immune Mechanism and Molecular Analyses of Tumors
2018 ASGCT presentation by Douglas Jolly, Ph.D., executive vice president of research and pharmaceutical development at Tocagen.
Review the presentation.
Toca 511-Mediated Prodrug Activator Gene Therapy: A Promising Therapeutic Strategy for Ovarian Cancer
2018 ASGCT poster presentation by Sara Collins, Ph.D., assistant scientist in the department of cell biology at the University of Miami Miller School of Medicine.
Review the poster.
PD-L1 Checkpoint Blockade Using a Single-Chain Variable Fragment Targeting PD-L1 Delivered by Retroviral Replicating Vector Enhances Anti-Tumor Effect in Cancer Models
2018 ASGCT poster presentation by Amy Lin, Ph.D., associate director of experimental virology at Tocagen.
Review the poster.
Replicating retroviruses for manipulation of the tumor immune ecosystem: preclinical and clinical outcomes
PEGS 2018 presentation by Douglas Jolly, Ph.D., executive vice president of research and pharmaceutical development at Tocagen.
Review the presentation.
Toca 511 & Toca FC: Evaluation of durable response rate in the post-resection setting and association with survival in patients with recurrent high grade glioma
AAN oral presentation by Timothy Cloughesy, M.D., director of the University of California, Los Angeles, Neuro-Oncology Program
Review the presentation.
Immune profile of tumor microenvironment helps predict response in patients treated with an investigational immunotherapeutic consisting of a retroviral replicating vector (Toca 511) and an extended-release formulation of 5-fluorocytosine (Toca FC)
AACR 2018 poster presentation by Derek Ostertag, Ph.D., senior director of R&D Diagnostics at Tocagen.
Review the poster.
A Phase 1b Study of Toca 511, a Retroviral Replicating Vector, Followed by Toca FC in Patients With Advanced Cancer
AACR 2018 poster presentation by Jaime Merchan, M.D., director, Phase 1 clinical trials program at Sylvester Comprehensive Cancer Center, part of UHealth, the University of Miami Health System; associate professor of medicine at the University of Miami Miller School of Medicine.
Review the poster.
Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics
SNO-SCIDOT oral presentation by Timothy Cloughesy, M.D., director of the University of California, Los Angeles, Neuro-Oncology Program.
Review the presentation.
Intravenous Delivery of Toca 511 in Patients With High Grade Glioma Results in Quantifiable Expression of Cytosine Deaminase in Tumor Tissue
SNO-SCIDOT poster presentation by Tiffany Montellano, Ph.D., medical science liaison at Tocagen.
Review the poster.
Intravenous delivery of Toca 511 in patients with high grade glioma results in quantifiable expression of cytosine deaminase in tumor tissue
SNO oral presentation by Tobias Walbert, M.D., Ph.D., co-director of the Hermelin Brain Tumor Center at Henry Ford Hospital.
Review the presentation.
Durable Responses Observed in IDH1 Wildtype and Mutant Recurrent High Grade Glioma with Toca 511 & Toca FC Treatment
SNO oral presentation by Timothy Cloughesy, M.D., director of the University of California, Los Angeles, Neuro-Oncology Program.
Review the presentation.
Toca 511 and 5-FC induces T cell-mediated antitumor immunity in a mouse glioma model which is enhanced by the addition of a therapeutic antibody against CTLA-4 and correlative with a reduction in memory T regulatory cells.
SNO poster presentation by Douglas Jolly, Ph.D., executive vice president of research and pharmaceutical development at Tocagen.
Review the poster.
Immunological activation in responding patients with recurrent HGG after treatment with Toca 511 & Toca FC: Results from a phase 1 trial
SNO e-talk by Derek Ostertag, Ph.D., director, R&D diagnostics at Tocagen.
Review the presentation.
T cell priming by Toca 511 and 5-FC coupled with T regulatory cell depletion by αCTLA-4 synergistically enhances anti-tumor immune memory in a mouse model of glioma
SITC poster presentation by Leah Mitchell, Ph.D., associate director, translational research at Tocagen.
Review the poster.
Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment
AACR-NCI-EORTC oral presentation by Clark Chen, M.D., Ph.D., Lyle French Chair in Neurosurgery and head of the University of Minnesota Medical School Department of Neurosurgery
Review the presentation.
Watch the webcast.
Long-term follow-up data from 126 patients with recurrent high grade glioma from three Phase 1 trials of Toca 511 and Toca FC: Update and justification for a Phase 2/3 trial.
ASGCT podium presentation by Douglas Jolly, Ph.D., executive vice president of research and pharmaceutical development at Tocagen.
Review the presentation.
TOCA 511 & 5-FC: Anti-tumor activity, immune memory and prolonged survival even at low infection levels.
ASGCT poster presentation by Kader Yagiz, Ph.D., research scientist at Tocagen.
Review the poster.
Publications
PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models.
Oncotarget.
2019; 10(23): 2252-2269.
Leah A. Mitchell, et al.
Read the article.
Molecular analyses support the safety and activity of retroviral replicating vector Toca 511 in patients.
Clin Cancer Res.
2018; 24(19): 4680-4693.
Daniel J. Hogan, et al.
Read the article.
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
Neuro-Oncol.
2018; 20(10): 1383–1392.
Timothy F. Cloughesy, et al.
Read the article.
Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
Neuro-Oncol.
2017; 19(7): 930-939.
Leah A. Mitchell, et al.
Read the article.
Retroviral replicating vector delivery of miR-PDL1 inhibits immune checkpoint PDL1 and enhances immune responses in vitro.
Mol. Ther. — Nucleic Acids.
2017; 6(3): 221-232.
Amy H. Lin, et al.
Read the article.
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
Sci. Transl. Med.
2016; 8(341): 341ra75.
Timothy F. Cloughesy, et al.
Read the article.
MethylMeter: bisulfite-free quantitative and sensitive DNA methylation profiling and mutation detection in FFPE samples.
Epigenomics.
2016; 8(6): 747-765.
David McCarthy, …Oscar Diago, et al.
Read the article.
Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Neuro-Oncol.
2016; 18(10): 1390-1401.
Kader Yagiz, et al.
Read the article.
A retroviral replicating vector encoding cytosine deaminase and 5-FC induces immune memory in metastatic colorectal cancer models.
Molecular Therapy Oncolytics.
2017; 8(3): 14-26.
Kader Yagiz, et al.
Read the article.
Efficient therapeutic protein expression using retroviral replicating vector with 2A peptide in cancer models.
Hum. Gene Ther.
2017; 29(4): 437-451.
Hofacre A. et al.
Read the article.
Extensive replication of a retroviral replicating vector can expand the A bulge in the encephalomyocarditis virus internal ribosome entry site and change translation efficiency of the downstream transgene.
Hum. Gene Ther. Methods.
2016; 27(2): 59-70.
Lin AH. et al.
Read the abstract.
Retroviral replicating vectors deliver cytosine deaminase leading to targeted 5-fluorouracil-mediated cytotoxicity in multiple human cancer types.
Hum. Gene. Ther. Methods.
2016; 27(1): 17-31.
Twitty CG. et al.
Read the abstract.
Intravenous administration of a retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in an orthotopic immune-competent mouse glioma model.
Hum. Gene Ther.
2015; 26(2): 82-93.
Huang T. et al.
Read the abstract.
Blockade of type I interferon (IFN) production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivity.
J Virol.
2014; 88(17): 10066-10077.
Lin AH. et al.
Read the abstract.
Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.
Cancer Gene Therapy.
2014; 21(10): 405-410.
Takahashi M. et al.
Read the abstract.
MicroRNA 142-3p attenuates spread of replicating retroviral vector in hematopoietic lineage-derived cells while maintaining an antiviral immune response.
Hum. Gene Ther.
2014; 25(8): 759-771.
Lin AH. et al.
Read the abstract.
Maintaining therapeutic activity in the operating room: Compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids.
Mol. Ther. — Methods & Clinical Development.
2014; 1, 14024.
Burnett R. et al.
Read the article.
Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Cancer Gene Therapy.
2013; 20(10): 544-551.
Huang TT. et al.
Read the abstract.
Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model.
Cancer Gene Therapy.
2013; 20(6): 336-334.
Dali Yin,….Harry E. Gruber, et al.
Read the article.
Not reinventing the wheel: Applying the 3Rs concepts to viral vector gene therapy biodistribution studies.
Human Gene Ther. Clin. Dev.
2013; 24: 1-4.
Timothy K. MacLachlan,…DJ. Jolly, et al.
Read the article.
Design and selection of Toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression.
Mol. Ther.
2012; 20(9): 1689-1698.
Perez O. and Logg C. et al.
Read the article.
Chapter eleven: Retroviral replicating vectors in cancer
Friedmann T. (ed) Gene Transfer Vectors for Clinical Application, Academic Press
2012; 11: 199-228.
Logg, C. R. et al.
Read the abstract.
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Neurooncol.
2012; 14(2): 145-159.
Ostertag D. et al.
Read the article. Read the supplementary data.